Bio-Rad Laboratories (NYSE:BIO) posted second-quarter earnings this evening that beat the consensus forecast on Wall Street.
The Hercules, Calif.–based life science research and clinical diagnostics manufacturer reported profits of $598.8 million, or $19.86 per share, on sales of $572.6 million for the three months ended June 30, for the bottom-line more than doubling and sales slightly declining compared with Q4 2017.
Adjusted to exclude one-time items, earnings per share were $1.57, 24¢ ahead of The Street, where analysts were looking for sales of $572.6 million.
“Performance in the second quarter reflects strength in many of our key product lines across our major geographies,” said Bio-Rad CEO Norman Schwartz.
The company continues to anticipate currency-neutral revenue growth of roughly 4.0% to 4.5% for the full year.